Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug;102(2):381-391.
doi: 10.1189/jlb.5VMR1016-449R. Epub 2017 Feb 8.

The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients

Richard P Tobin  1 , Dana Davis  1 , Kimberly R Jordan  2 , Martin D McCarter  3
Affiliations
Review

The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients

Richard P Tobin et al. J Leukoc Biol. 2017 Aug.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that represent a formidable obstacle to the successful treatment of cancer. Patients with high frequencies of MDSCs have significantly decreased progression-free survival (PFS) and overall survival (OS). Whereas there is experimental evidence that the reduction of the number and/or suppressive function of MDSCs in mice improves the efficacy of anti-cancer therapies, there is notably less evidence for this therapeutic strategy in human clinical trials. Here, we discuss currently available data concerning MDSCs from human clinical trials and explore the evidence that targeting MDSCs may improve the efficacy of cancer therapies.

Keywords: MDSC; immunosuppression; immunotherapy; oncology.

PubMed Disclaimer

References

    1. Hodi, F. S. , O'Day, S. J. , McDermott, D. F. , Weber, R. W. , Sosman, J. A. , Haanen, J. B. , Gonzalez, R. , Robert, C. , Schadendorf, D. , Hassel, J. C. , Akerley, W. , van den Eertwegh, A. J. , Lutzky, J. , Lorigan, P. , Vaubel, J. M. , Linette, G. P. , Hogg, D. , Ottensmeier, C. H. , Lebbé, C. , Peschel, C. , Quirt, I. , Clark, J. I. , Wolchok, J. D. , Weber, J. S. , Tian, J. , Yellin, M. J. , Nichol, G. M. , Hoos, A. , Urba, W. J. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723. - PMC - PubMed
    1. Larkin, J. , Chiarion‐Sileni, V. , Gonzalez, R. , Grob, J. J. , Cowey, C. L. , Lao, C. D. , Schadendorf, D. , Dummer, R. , Smylie, M. , Rutkowski, P. , Ferrucci, P. F. , Hill, A. , Wagstaff, J. , Carlino, M. S. , Haanen, J. B. , Maio, M. , Marquez‐Rodas, I. , McArthur, G. A. , Ascierto, P. A. , Long, G. V. , Callahan, M. K. , Postow, M. A. , Grossmann, K. , Sznol, M. , Dreno, B. , Bastholt, L. , Yang, A. , Rollin, L. M. , Horak, C. , Hodi, F. S. , Wolchok, J. D. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34. - PMC - PubMed
    1. Chen, D. S. , Mellman, I. (2013) Oncology meets immunology: the cancer‐immunity cycle. Immunity 39, 1–10. - PubMed
    1. Kumar, V. , Patel, S. , Tcyganov, E. , Gabrilovich, D. I. (2016) The nature of myeloid‐derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208–220. - PMC - PubMed
    1. Talmadge, J. E. , Gabrilovich, D. I. (2013) History of myeloid‐derived suppressor cells. Nat. Rev. Cancer 13, 739–752. - PMC - PubMed

Publication types

MeSH terms